Scarica l'app Stockscreener
23.46
0.39%
0.09
Dopo l'orario di chiusura:
23.46
Precedente Chiudi:
$23.37
Aprire:
$23.72
Volume 24 ore:
1.95M
Relative Volume:
1.04
Capitalizzazione di mercato:
$1.63B
Reddito:
$18.09M
Utile/perdita netta:
$-208.87M
Rapporto P/E:
-6.679
EPS:
-3.5125
Flusso di cassa netto:
$-178.15M
1 W Prestazione:
-38.63%
1M Prestazione:
-49.25%
6M Prestazione:
+36.71%
1 anno Prestazione:
-56.95%
Intervallo 1D:
$22.71
$23.72
Intervallo di 1 settimana:
$22.47
$39.66
Portata 52W:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Nome
Uniqure Nv
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
23.46 | 2.65B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure Nv Borsa (QURE) Ultime notizie
Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - statnews.com
$uniQure NV (QURE.US)$ - Moomoo
uniQure N.V. (QURE) Securities Fraud InvestigationLevi & Korsinsky - ACCESS Newswire
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.
UniQure Price Target Cut to $31.00/Share From $46.00 by Goldman Sachs - Moomoo
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha
uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance
Is uniQure (NASDAQ:QURE) Rewriting the Healthcare Stocks Playbook Today? - Kalkine Media
H.C. Wainwright reiterates uniQure stock rating citing trial data By Investing.com - Investing.com Nigeria
uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha
Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView
UNIQURE N.V.MEAN CSF NFL 6% BELOW BASELINE AT 36 MONTHS FOR 14 HIGH-DOSE PATIENTS - webull.com
Why uniQure shares are sinking after AMT-130 update - The Economic Times
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar
Top Midday Decliners - Moomoo
uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit - Yahoo Finance
UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble - marketscreener.com
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE) - Seeking Alpha
uniQure N.V. stock Analysis: 37% Crash Highlights Oversold Risks - The Cryptonomist
uniQure Sheds Nearly Half Its Value as 48-Month Huntington's Data Disappoints - finance.biggo.com
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression SlowingSlideshow (NASDAQ:QURE) 2026-09-29 - Seeking Alpha
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law - Business Wire
uniQure reports 48-month data for Huntington’s disease therapy By Investing.com - Investing.com Nigeria
Pattern recognition? Uniqure dips on new HD results - BioWorld News
uniQure tanks is it reports new data from Phase I/II studies of ifezuntirgene inilparvovec - The Pharma Letter
Why is uniQure stock collapsing today? By Investing.com - Investing.com Australia
QURE Investor Alert: uniQure Securities InvestigationKehoe Law Firm, P.C. - True North Radio Network
Why Is uniQure Stock Sinking on Tuesday? - Yahoo Finance
Form 8K uniQure N.V. For: 29 September By Investing.com - Investing.com South Africa
Stifel reiterates uniQure stock rating on Huntington’s data By Investing.com - Investing.com Nigeria
uniQure Highlights Long-Term AMT-130 Huntington’s Data - TipRanks
uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update - Yahoo Finance
ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update - Yahoo Finance
uniQure: AMT-130 phase I/II data show sustained functional benefit at 36–48 months - TradingView
uniQure: 80% Slowing on Huntington's Score at 3 Years - Stock Titan
uniQure (QURE) Shares Plunge Over 50% Premarket After Mixed AMT-130 Huntington's Data - GuruFocus
QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know - Yahoo Finance
ClearPoint Neuro stock tumbles on uniQure trial setback - Investing.com
UniQure plunges as Huntington's trial data disappoints investors - marketscreener.com
uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat - Yahoo Finance
uniQure posts new data for Huntington’s disease drug (QURE) - Seeking Alpha
QURE Stock Whipsaws As Traders Weigh Cash Pile Against Heavy Losses - StocksToTrade
Why is uniQure stock collapsing today? - Investing.com
uniQure Announces Additional Data from Ongoing Phase I/II - GlobeNewswire
UniQure’s gene therapy continues to slow Huntington’s progression after four years - statnews.com
UniQure Sinks After Worse-Than-Expected Huntington’s Results - Bloomberg.com
Trading the Move, Not the Narrative: (QURE) Edition - Stock Traders Daily
QURE Stock Price, Quote & Chart - ChartMill
Uniqure Nv Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure Nv Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Jul 02 '26 |
Sale |
45.16 |
21,082 |
952,051 |
519,227 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Option Exercise |
5.59 |
10,000 |
55,900 |
178,235 |
| Abi-Saab Walid | Chief Medical Officer |
Jun 30 '26 |
Sale |
46.42 |
30,000 |
1,392,600 |
148,235 |
| Kaye Jack | Director |
Jun 30 '26 |
Option Exercise |
23.44 |
21,167 |
496,230 |
43,056 |
| Kaye Jack | Director |
Jun 30 '26 |
Sale |
46.44 |
21,167 |
983,030 |
25,996 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):